New Jersey S4017 mandates the Department of Health to buy and distribute xylazine test strips to harm reduction service providers.
New Jersey S4017 requires the Department of Health to establish a program for purchasing and distributing xylazine test strips to entities offering authorized harm reduction services. The Department will oversee the bulk purchasing and distribution of these test strips upon request, and maintain a website with information about the strips and their availability. The program will be funded by federal and state appropriations. The Commissioner of Health can adopt necessary rules and regulations to implement the act.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.